Marico Q1 FY26 revenue rose 23%; profit up 8%, resurfacing its early-August India business update

Marico's early-August report showed Q1 FY26 consolidated revenue of Rs 3,259 crore, up 23.3% year on year, while net profit rose 8.2% to Rs 513 crore. India revenue grew 27.2%, international revenue rose 12.9%, and the company increased its fully diluted stake in Plix maker Satiya Nutraceuticals to 60%.

— FiledWed, 2 Sept, 2026, 07:48 IST·First seen Wed, 2 Sept, 2026, 07:48 IST·Source Financial Express · BrandWagon

What happened

Marico posted Q1 FY26 profit growth of 8.2% and revenue growth of 23.3%, led by a 27.2% rise in India sales. The company increased its stake in Plix maker

Key facts

  • Q1 FY26 consolidated net profit: Rs 513 crore, up 8.2% YoY from Rs 474 crore
  • Revenue from operations: Rs 3,259 crore, up 23.31% YoY from Rs 2,643 crore
  • Total income: Rs 3,315 crore
  • Other income: Rs 56 crore
  • Total expenses: Rs 2,659 crore versus Rs 2,075 crore
  • India revenue: Rs 2,495 crore, up 27.17% YoY from Rs 1,962 crore
  • International revenue: Rs 764 crore, up 12.91% YoY from Rs 681 crore
  • India PBT: Rs 469 crore
  • International PBT: Rs 213 crore
  • Marico increased Satiya Nutraceuticals stake to 60% fully diluted

Why this matters

Increasing its stake in Plix maker Satiya Nutraceuticals to 60% deepens Marico’s exposure to the fast-growing health and wellness category and strengthens its premium portfolio optionality.

What to watch

  • Volume growth versus price/mix contribution in the India business.
  • Gross-margin trend and management commentary on copra, edible oil, packaging and currency costs.
  • Advertising-to-sales ratio and whether profit growth closes the gap with 23.3% revenue growth.
  • Plix revenue growth, distribution expansion, profitability and degree of post-acquisition consolidation impact.
  • Rural demand indicators, urban discretionary consumption and modern-trade/e-commerce growth.
  • International constant-currency growth, Bangladesh and Vietnam demand conditions, and foreign-exchange effects.
  • Increase investment in Plix/Satiya Nutraceuticals distribution, innovation and digital marketing following the stake increase to 60%.
  • Prioritize premiumisation in foods, health, personal care and value-added hair-care formats to raise mix and reduce dependence on core commoditized categories.
  • Use broad India distribution gains to deepen rural and direct-reach penetration while selectively taking price actions if copra or edible-oil costs rise.
  • Step up advertising and promotional spending to defend category share, accepting a temporary gap between revenue and profit growth.
  • Pursue bolt-on investments or partnerships in wellness, nutrition and digital-native FMCG brands if early Plix integration metrics are favorable.